Pazopanib clinical trial data interpretation and patient guidance suggestions

Pazopanib is an oral multi-target tyrosine kinase inhibitor that mainly acts on vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-KIT. It is widely used in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Multiple clinical trials have shown that pazopanib has significant advantages in prolonging progression-free survival (PFS) and improving overall survival rate, providing patients with an effective treatment option.

In key clinical phase III trials (such as VEG105192), pazopanib significantly prolonged the progression-free survival of patients with advanced renal cell carcinoma compared with placebo, with the median PFS extending from 4.2 months to 9.2 months, showing good anti-tumor activity. The trial also confirmed that pazopanib has good safety and tolerance. Common adverse reactions include hypertension, fatigue, diarrhea and abnormal liver function, but most of them are controllable.

While taking pazopanib, patients need to follow the doctor's guidance, regularly monitor blood pressure, liver function and heart function, and promptly detect and deal with drug-related adverse reactions. In particular, liver function monitoring is very critical, because pazopanib may cause an increase in liver enzymes, and in severe cases, the medication may need to be suspended or the dose adjusted. At the same time, patients should pay attention to a reasonable diet and avoid simultaneous use with other drugs that affect liver metabolism to reduce the risk of drug interactions.
Overall, the efficacy and safety of pazopanib in clinical trials have brought new hope to patients with advanced renal cell carcinoma and soft tissue sarcoma. Patients should use it rationally under the guidance of professional doctors, actively cooperate with follow-up and monitoring, and report any symptoms of discomfort in a timely manner to ensure the smooth progress of treatment and improvement of quality of life.
Reference: https://www.drugs.com/